How Lanfear was paid
$2.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Dennis M. LanfearPresident, Chief Executive Officer and Chairman of the Board of Directors | $1,026,545 | $828,130 | $869,295 | $12,904 | $2,736,874 |
| Bryan McMichaelChief Financial Officer | $543,688 | $314,192 | $237,697 | $7,500 | $1,103,077 |
| Paul ReiderFormer Chief Commercial Officer | $217,742 | $347,760 | — | $662,022 | $1,227,524 |
What changed and why
- $2.7MDennis M. Lanfear received a total compensation of $2,736,874 in fiscal 2025.
- 92%Corporate goals were achieved at 92% under the annual bonus plan for NEOs.
- 54.27%Stockholders approved the 2025 say-on-pay vote with 54.27% support.
- The company updated its peer group in September 2025 to focus on innovative oncology.
- Paul Reider resigned as Chief Commercial Officer effective April 30, 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.